Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Molecular Weight:
327.33
Purity:
99.96%
CAS Number:
[70806-55-2]
Formula:
C18H17NO5
Target:
RAAS
T2270
* VAT and and shipping costs not included. Errors and price changes excepted